Critical Closing Pressure and PCO₂ Gap in Fluid Resuscitation for Septic Shock

1. Study Background Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, with septic shock being a subset of sepsis. Septic shock is defined as persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥65 mmHg and serum lactate >2 mmol/L despite adequate fluid resuscitation. The mortality rate associated with sepsis ranges from 13.1% to 35.5%, and its increasing incidence has led to significant healthcare resource utilization and economic burden. Early recognition and timely treatment are critical for patients with sepsis and septic shock. Hemodynamics play a central role in sepsis resuscitation. The core issue in shock is inadequate cellular oxygen utilization, making the goal of shock therapy to increase oxygen delivery to meet demand and address systemic hypoperfusion. Carbon dioxide (CO₂), as a byproduct of cellular oxygen metabolism, has garnered attention. The venous-to-arterial CO₂ gap (PvaCO₂) and critical closing pressure (Pcrit) are emerging as potential markers for evaluating fluid responsiveness and tissue perfusion. However, their clinical utility remains controversial due to conflicting results and the influence of factors such as hemoglobin, pH, and the Haldane effect. This study aims to explore the dynamic changes in PvaCO₂ and CvaCO₂ during fluid resuscitation and investigate the role of Pcrit and tissue perfusion pressure (TPP) in risk stratification and blood pressure management for septic shock patients.
2. Study Objectives To evaluate the predictive value of ΔPvaCO₂ (change in PvaCO₂) for fluid responsiveness in septic shock patients. To assess the contributions of VCO₂, the Haldane effect, and cardiac output (CO) to changes in PvaCO₂ and CvaCO₂ during fluid resuscitation. To investigate the role of Pcrit and TPP in risk stratification and their potential as additional targets for blood pressure management in sepsis.
3. Methods and Procedures Study Design: Prospective observational study in ICU patients with septic shock.

Participants:

Inclusion Criteria:

Age 18-80 years.

Diagnosis of septic shock per Sepsis-3 criteria.

Requirement for invasive hemodynamic monitoring (arterial and central venous catheters).

Clinical indication for fluid challenge (e.g., hypotension, signs of hypoperfusion).

Exclusion Criteria:

Pregnancy or lactation.

Other types of shock (e.g., cardiogenic, obstructive).

Mechanical circulatory support (e.g., ECMO, IABP).

Severe respiratory or cardiovascular contraindications.

Data Collection:

Demographics and Clinical Data: Age, gender, SOFA/APACHE II scores, infection source, comorbidities, 28-day mortality.

Laboratory Tests: Lactate, hemoglobin, ScvO₂, SaO₂, arterial/venous blood gases.

Hemodynamic Monitoring:

Continuous MAP, CVP, and CO measurements (via PiCCO or echocardiography).

VO₂ and VCO₂ monitoring using a metabolic cart.

Fluid Challenge: 500 mL of 4% gelatin administered over 15 minutes, with hemodynamic and metabolic measurements pre- and post-infusion.

Pcc and Pmsf Measurement Protocol :

Interrupt Spontaneous Breathing: Temporarily suspend patient-triggered ventilation to ensure controlled mechanical ventilation.Adjust Ventilator to Pressure Control (PC) Mode: Apply incremental airway pressures of 5, 15, 25, and 35 cmH₂O, each maintained for 12 seconds.

Hemodynamic Data Acquisition:

Continuous Cardiac Output (CCO): Recorded on a beat-to-beat basis and averaged over the 12-second interval (displayed on monitor).

Additional Parameters: Simultaneously measure:Arterial pressure (systolic, diastolic), Heart rate (HR), Central venous pressure (CVP),Repetition: Each pressure level is tested 3 times to ensure reproducibility.

Data Analysis:

CO-MAP Regression: Plot cardiac output (CO) against mean arterial pressure (MAP) for each airway pressure.Pcrit Determination: The y-intercept of the CO-MAP curve represents critical closing pressure (Pcrit).CO-CVP Regression: Plot CO against CVP to derive mean systemic filling pressure (Pmsf) as the y-intercept.Pcrit and TPP: Derived from MAP-CO regression curves (TPP = MAP - Pcrit).

Measurement of VO₂ and VCO₂ Using Dräger Ventilators：1. Equipment Setup Ventilator Model: Dräger Evita V800, XLUNGE module (or equivalent with metabolic monitoring capabilities).

Required Accessories:

D-lite™ or Pediatric Flow Sensor: Installed between the endotracheal tube and ventilator circuit.

Gas Sampling Line: Connected to the flow sensor and ventilator's gas analyzer. Calibration Syringe: For flow sensor calibration. 2. Pre-Measurement Checks Calibration:Perform auto-calibration of the flow sensor and gas analyzer (follow ventilator prompts).

Verify O₂ and CO₂ sensor accuracy with known gas mixtures if available.

Circuit Integrity:

Ensure no air leaks around the endotracheal tube or sensor. Confirm gas sampling line is patent and dry (replace if contaminated with secretions).

1. Measurement Protocol

Stabilization Phase:

Maintain steady-state ventilation for ≥5 minutes (fixed FiO₂, PEEP, and tidal volume).

Pause endotracheal suctioning and discontinue humidification temporarily (water vapor interferes with gas analysis).

Data Acquisition:

Activate the XLUNGE metabolic module or equivalent. Select "Metabolic Monitoring" mode to display real-time VO₂ (O₂ consumption) and VCO₂ (CO₂ production).

Measurement Duration: Record values over ≥3 minutes to average respiratory cycle variability.

Key Parameters:

VO₂ (mL/min): Derived from O₂ uptake ([FiO₂ × inspired volume] - [FeO₂ × expired volume]).

VCO₂ (mL/min): Calculated from CO₂ elimination ([FeCO₂ × expired volume] - [FiCO₂ × inspired volume]).

Respiratory Quotient (RQ): Auto-calculated as VCO₂/VO₂.

Statistical Analysis:

Sample size: 48 patients (accounting for 20% dropout). Correlation analysis (Pearson/Spearman), ROC curves for predictive performance, and Cox regression for prognostic modeling.

1. Outcome Measures Primary Outcome: Change in cardiac output (CO) after fluid resuscitation. Secondary Outcomes: Lactate clearance, ICU length of stay, vasopressor requirements, 24-hour fluid balance.
2. Quality Control Standardized protocols for data collection and monitoring. Two independent physicians for eligibility assessment. Electronic medical record verification for baseline data.
3. Ethical Considerations Informed consent will be obtained from all participants or their legal representatives.

Patient data will be anonymized to ensure confidentiality.

The study complies with the Declaration of Helsinki and local regulatory requirements.

1. Statistical Methods Software: SPSS 27.0, GraphPad Prism 10.0, PASS 2021.

Tests: Shapiro-Wilk for normality, t-tests/Wilcoxon for group comparisons, ROC analysis for predictive accuracy.

Significance Level: P < 0.05.